|
MechanismNCOA3 modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with CoRegen, Inc.
0 Patents (Medical) associated with CoRegen, Inc.
100 Deals associated with CoRegen, Inc.
100 Translational Medicine associated with CoRegen, Inc.